Werbung
Werbung

BTAI

BTAI logo

BioXcel Therapeutics, Inc. Common Stock

2.00
USD
Gesponsert
-0.04
-1.76%
08. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

2.00

-0.01
-0.45%

BTAI Ergebnisberichte

Positives Überraschungsverhältnis

BTAI übertreffen die 14 der letzten 31Schätzungen.

45%

Nächster Bericht

Datum des nächsten Berichts
25. März 2026
Estimate for Q4 25 (Revenue/ EPS)
$178.50K
/
-$0.83
Implizierte Änderung von Q3 25 (Revenue/ EPS)
+82.14%
/
-61.93%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
-51.23%
/
-76.75%

BioXcel Therapeutics, Inc. Common Stock earnings per share and revenue

On 12. Nov. 2025, BTAI reported earnings of -2.18 USD per share (EPS) for Q3 25, missing the estimate of -1.20 USD, resulting in a -81.50% surprise. Revenue reached 98.00 tausend, compared to an expected 216.75 tausend, with a -54.79% difference. The market reacted with a -15.35% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.83 USD, with revenue projected to reach 178.50 tausend USD, implying an decrease of -61.93% EPS, and increase of 82.14% in Revenue from the last quarter.
FAQ
For Q3 2025, BioXcel Therapeutics, Inc. Common Stock reported EPS of -$2.18, missing estimates by -81.5%, and revenue of $98.00K, -54.79% below expectations.
The stock price moved down -15.35%, changed from $2.02 before the earnings release to $1.71 the day after.
The next earning report is scheduled for 25. März 2026.
Based on 6 analysts, BioXcel Therapeutics, Inc. Common Stock is expected to report EPS of -$0.83 and revenue of $178.50K for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung